Is PT-141 (Bremelanotide) Legal in Missouri?

What PT-141 (Bremelanotide) Is and Why Legality Matters

PT-141, generically known as bremelanotide, is a synthetic melanocortin receptor agonist that acts centrally on MC3R and MC4R receptors in the brain rather than working through vascular mechanisms the way phosphodiesterase-5 inhibitors do. Palatin Technologies developed it from the melanocortin peptide MT-II, and it was eventually approved by the FDA as Vyleesi in June 2019 [1].

Because bremelanotide is a regulated prescription drug with an approved brand-name product, its legal status is not a gray area the way some research peptides are. The question for Missouri residents is not whether it is legal in principle, but whether the specific product, source, and prescribing arrangement meet federal and state requirements.

The FDA Approval That Changed Everything

Before June 21, 2019, bremelanotide existed in a genuine regulatory gray zone. Compounding pharmacies sometimes prepared it from bulk API for off-label use, and enforcement was inconsistent. The FDA approval of Vyleesi (bremelanotide) 1.75 mg subcutaneous autoinjector for hypoactive sexual desire disorder in premenopausal women resolved that ambiguity [2]. Once a drug has an approved application, federal law under 21 U.S.C. § 353a and § 353b imposes additional compounding restrictions.

What the Phase III Trials Actually Showed

The FDA approval rested on two key randomized controlled trials, RECONNECT Study 1 and Study 2, which together enrolled 1,267 premenopausal women with generalized acquired HSDD. Clayton et al. (2016) reported that bremelanotide produced a statistically significant increase in satisfying sexual events compared with placebo (P<0.001) and a significant reduction in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) [3]. A mean increase of 0.5 satisfying sexual events per month over placebo was recorded at the primary endpoint. The drug's approval was based on this modest but statistically significant and patient-meaningful benefit.

Off-label data for erectile dysfunction in men is more limited. A 2007 pilot study by Safarinejad (N=84) showed bremelanotide produced erections sufficient for intercourse in men with psychogenic or mixed-etiology ED, though no Phase III trial in men has reached the FDA [4].

Federal Legal Framework Governing Bremelanotide

Federal law controls the manufacture, distribution, and dispensing of bremelanotide regardless of which state a patient lives in. Missouri adds one additional layer of state pharmacy and medical practice law on top of that federal floor.

Prescription Drug Status Under the FDCA

Bremelanotide meets the definition of a prescription drug under the Federal Food, Drug, and Cosmetic Act because it is not safe for use without professional supervision. 21 C.F.R. § 201.100 requires that prescription drugs be dispensed only upon a valid prescription from a licensed practitioner [5]. Selling or purchasing Vyleesi or any compounded bremelanotide without that prescription constitutes misbranding under federal law and can result in criminal penalties.

Bremelanotide is not a DEA-scheduled controlled substance. The DEA Controlled Substances list does not include bremelanotide as of the most recent update [6]. That means prescribers do not need a DEA Form 222 or any special DEA registration to prescribe it beyond their standard DEA number, and patients do not face the additional restrictions that apply to Schedule II-IV drugs.

503A Compounding Pharmacies and Bremelanotide

Section 503A of the FDCA, codified at 21 U.S.C. § 353a, allows a licensed pharmacist or physician to compound a drug for an identified individual patient if several conditions are met [7]. The compounded preparation must be based on a valid prescription for that specific patient. It cannot be a copy of a commercially available drug unless the prescriber documents a clinical difference, such as a patient's need for a different concentration, preservative-free formulation, or route of administration not available in the commercial product.

Bremelanotide's placement on any nominated bulk-drug list matters here. The FDA's 503A bulks list does not currently include bremelanotide as a nominated or evaluated substance [8]. That means 503A pharmacies cannot compound it from raw bulk API under the bulks pathway. They CAN compound it from the FDA-approved Vyleesi product itself if they are making a preparation that is clinically differentiated and patient-specific. Some compounding pharmacies prepare alternate concentrations or preservative-free versions of Vyleesi on this basis. Missouri-licensed 503A pharmacies operating under this framework are acting within the law.

503B Outsourcing Facilities Are Prohibited From Compounding Bremelanotide

Section 503B outsourcing facilities operate under different rules. They may compound without patient-specific prescriptions and in larger volumes, but only from substances on the FDA 503B bulk-drug list [9]. Bremelanotide does not appear on that list. A 503B facility compounding bremelanotide would be violating federal law, and any product purchased from such a source cannot be presumed compliant. Patients should verify their pharmacy's 503A registration through the Missouri Board of Pharmacy license verification portal or the FDA's list of registered 503B outsourcing facilities.

Missouri State Law and Bremelanotide

Missouri does not have a separate state statute that specifically addresses PT-141 or bremelanotide. What Missouri does have is a comprehensive pharmacy practice act and a medical practice act that implement the federal framework and add state-level enforcement.

Missouri Board of Pharmacy Rules

The Missouri Board of Pharmacy operates under Chapter 338 of the Missouri Revised Statutes, which governs pharmacy practice, compounding, and dispensing [10]. Missouri has adopted rules consistent with the federal 503A framework, requiring that compounded preparations be made for individual patients based on valid prescriptions, prepared by licensed pharmacists in registered facilities, and not routinely copied from commercial products without clinical justification.

A Missouri-licensed 503A compounding pharmacy that prepares a patient-specific bremelanotide formulation, with documentation of clinical necessity, is operating legally under both state and federal law. The pharmacy must maintain appropriate beyond-use dating, sterility testing for injectable preparations, and dispensing records as required by Missouri Code of State Regulations 20 CSR 2220-6.040 [11].

Missouri Medical Practice Act and Prescriber Authority

Any physician, advanced practice registered nurse, or physician assistant licensed in Missouri may prescribe bremelanotide for an FDA-approved indication or, importantly, for an off-label use if it is grounded in sound medical judgment. The Missouri Medical Practice Act, Chapter 334 RSMo, does not restrict off-label prescribing [12]. Off-label prescribing of FDA-approved drugs is a recognized and legal medical practice, as noted by the FDA's own guidance on off-label use [13].

This means a Missouri prescriber can legally write a prescription for bremelanotide for a man with erectile dysfunction or a postmenopausal woman with sexual arousal disorder, even though those indications are not in the FDA label.

Telehealth Prescribing in Missouri

Missouri permits telehealth prescribing for non-controlled substances when a valid patient-provider relationship exists. Missouri SB 1007 (2018) and subsequent telehealth parity regulations allow licensed Missouri providers to evaluate patients and prescribe drugs including bremelanotide via synchronous audio-visual telehealth visits [14]. Because bremelanotide is not a controlled substance, it does not face the additional prescribing restrictions imposed on Schedule II-IV drugs under the Ryan Haight Act.

A patient in Kansas City, St. Louis, Springfield, or any rural Missouri county can therefore receive a legitimate bremelanotide prescription through a telehealth visit with a licensed Missouri provider, provided the provider conducts a thorough medical evaluation, documents the clinical indication, and issues a prescription to a licensed Missouri pharmacy.

How to Get PT-141 (Bremelanotide) Legally in Missouri

Getting bremelanotide through legitimate channels in Missouri involves three steps: a valid clinical evaluation, a prescription from a licensed provider, and dispensing through an approved pharmacy.

Step 1: Clinical Evaluation and Prescription

A qualifying patient should seek evaluation from a Missouri-licensed physician, APRN, or PA with experience in sexual medicine, endocrinology, urology, gynecology, or a related specialty. The provider should take a detailed sexual health history, screen for contributing factors such as hormonal deficiency, depression, relationship factors, and medication side effects, and document the clinical rationale for bremelanotide. The International Society for the Study of Women's Sexual Health (ISSWSH) 2019 position statement recommends a biopsychosocial assessment before initiating pharmacotherapy for HSDD [15].

The prescription must specify the patient's name, the drug name, dose, route, quantity, and the prescriber's DEA number and Missouri license number.

Step 2: Choosing the Right Pharmacy

Patients have two main options. First, they may fill the prescription for brand-name Vyleesi at any Missouri retail or specialty pharmacy that carries or can order it. Vyleesi is FDA-approved and manufactured under GMP standards, so product quality is not a concern. Insurance coverage is limited; the FDA label for Vyleesi notes a cost-assistance program through the manufacturer, Palatin/AMAG [2].

Second, patients with a clinical need for a different formulation, such as a lower dose concentration or preservative-free preparation for injection sensitivity, may use a Missouri-licensed 503A compounding pharmacy. The prescriber must document the clinical differentiation. Patients should confirm the pharmacy's Missouri Board of Pharmacy registration before filling.

Step 3: Avoiding Illegal Sources

Research-chemical websites, online vendors that do not require a prescription, and gray-market peptide suppliers cannot legally sell bremelanotide in the United States. The FDA's guidance on purchasing prescription drugs online is unambiguous: prescription drugs sold without a valid prescription from a licensed provider are misbranded, and purchasing them carries legal and safety risks [16]. Products from unregulated sources may contain incorrect doses, impurities, or microbial contamination, none of which are subject to GMP oversight.

The HealthRX clinical team uses a three-gate review before any PT-141 prescription is issued: confirmed indication (HSDD diagnosis via validated DSDS screening or documented off-label clinical rationale), exclusion of contraindications (cardiovascular disease, uncontrolled hypertension, use of naltrexone), and pharmacy verification (Missouri Board of Pharmacy active license confirmed). Patients who do not clear all three gates are referred for additional workup before prescribing proceeds.

Safety Profile, Contraindications, and Clinical Monitoring

Bremelanotide's safety data come primarily from the RECONNECT trials and the FDA's post-marketing pharmacovigilance database. The FDA-approved prescribing information identifies transient blood pressure increases as the primary cardiovascular signal [2].

Blood Pressure and Cardiovascular Risk

In the RECONNECT trials, a transient mean maximum decrease in systolic blood pressure of approximately 2 mmHg and an initial increase occurring around 12 minutes post-dose were observed. Simon et al. (2019) noted that women with cardiovascular disease were excluded from the key trials, and the FDA label carries a contraindication for patients at high cardiovascular risk [15]. Missouri prescribers should measure baseline blood pressure and avoid prescribing bremelanotide to patients with known cardiovascular disease or uncontrolled hypertension above 140/90 mmHg.

Nausea and Tolerability

Nausea was the most common adverse event in the RECONNECT program, occurring in approximately 40% of bremelanotide-treated patients versus 1.3% placebo, with most episodes described as mild to moderate and self-limiting within 30 minutes. The FDA's Summary Review document recommends taking the injection 45 minutes before anticipated sexual activity and not exceeding one dose per 24 hours [17]. Prescribers in Missouri should counsel patients on this timing to minimize nausea severity.

Drug Interactions

Bremelanotide slows gastric emptying and may reduce the rate of absorption of orally administered drugs. The FDA label specifically warns against co-administration with naltrexone, as bremelanotide substantially reduces naltrexone plasma concentrations [2]. Patients on naltrexone for alcohol use disorder or opioid use disorder should not receive bremelanotide. No significant interaction with hormonal contraceptives was observed in the pharmacokinetic studies cited in the label.

Who Qualifies as a Candidate in Missouri

The FDA-approved indication is HSDD in premenopausal women. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), classifies HSDD-equivalent presentations under Female Sexual Interest/Arousal Disorder (FSIAD), characterized by absent or reduced sexual interest lasting at least 6 months and causing clinically significant distress [18]. Missouri clinicians using the DSM-5 framework will document an FSIAD or HSDD diagnosis to support the prescription.

Off-label, some Missouri providers prescribe bremelanotide for men with psychogenic or mixed-etiology erectile dysfunction who have not responded adequately to PDE5 inhibitors, and for postmenopausal women with HSDD, though these uses are not FDA-approved and require explicit informed consent and documentation.

Patients with the following should not receive bremelanotide: known cardiovascular disease, uncontrolled hypertension, pregnancy, or concurrent naltrexone use. A baseline metabolic panel and blood pressure measurement are the minimum workup before initiating therapy.

Regulatory Compliance Checklist for Missouri Providers

Missouri providers prescribing bremelanotide should maintain a documentation standard that covers the following elements. The prescriber should record the clinical indication using a validated instrument such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS) [19]. The record should note that alternative treatments, including psychotherapy and hormonal evaluation, were considered or attempted. The pharmacy dispensing the product should be identified by name and Missouri Board of Pharmacy license number. Any compounded preparation should include documentation of the clinical differentiation from the commercial Vyleesi product.

Following these documentation standards aligns with guidance from the American College of Obstetricians and Gynecologists (ACOG) and the Endocrine Society's position that off-label prescribing requires informed consent and documented clinical rationale [20].